InvivoSciences, Inc. (IVS) is a pre-clinical-stage biotech company focused on developing therapies for cardiovascular and cardiometabolic diseases. Our Kokordia™ technology platform integrates patient-derived micro heart models (NuHeart™) and AI-assisted clinical trial enrichment diagnostics. Kokordia™ improves the efficacy of clinical trials cost-efficiently by improving the statistical significance with fewer patients, supporting precision medicine in the cardiovascular domain. Our leading pipeline, IVS201, targets a specific heart failure subtype with preserved ejection fraction (HFpEF) identified through Kokordia™. It addresses interstitial cardiac fibrosis, normalizing diastolic stiffness and hyper-contractility. IVS is actively seeking funding and partnerships to advance its heart failure drug development programs and support partners’ precision medicine initiatives.